Atherosclerotic cardiovascular (CV) disease (ASCVD) incidence and mortality rates are
declining in many countries in Europe, but it is still a major cause of morbidity and mortality …

Background: Glucagon-like peptide 1 receptor agonists (GLP1-RA) and sodium-glucose
cotransporter-2 inhibitors (SGLT2i) have emerged as 2 new classes of antihyperglycemic …

Background Four glucagon-like peptide-1 (GLP-1) receptor agonists that are structurally
similar to human GLP-1 have been shown to reduce the risk of adverse cardiovascular …

Background Sodium-glucose co-transporter-2 (SGLT2) inhibitors have shown beneficial
effects on renal outcomes mainly in patients with established atherosclerotic cardiovascular …

Aims The expression of GADD153 (growth arrest and DNA damage-inducible gene 153), an
apoptosis-regulated gene, increases during endoplasmic reticulum (ER) stress. How …

Despite the decades-old knowledge that diabetes mellitus is a major risk factor for
cardiovascular disease, the reasons for this association are only partially understood. While …

Background In a randomized, controlled trial that compared liraglutide, a glucagon-like
peptide 1 analogue, with placebo in patients with type 2 diabetes and high cardiovascular …

The increasing prevalence of diabetes and its complications, such as cardiovascular and
kidney disease, remains a huge burden globally. Identification of biomarkers for the …

Management of diabetic kidney disease (DKD) has evolved in parallel with our growing
understanding of the multiple interrelated pathophysiological mechanisms that involve …

La tarea de elaboración de GPC incluye la creación de herramientas educativas y
programas de implementación de las recomendaciones. Para su implementación, se …